Wtta 2027: What Global MSP and Contingent Workforce Programmes Must Do About Their Dutch Supplier Base

Briefing for MSP programme managers, supplier relationship managers, contingent workforce directors and procurement leads responsible for Dutch supplier populations. Last reviewed 30 August 2026.

On 11 November 2025 the Netherlands adopted the Wet toelating terbeschikkingstelling van arbeidskrachten (Wtta) — the Labour Provision Admission Act. From 1 January 2027 it replaces simple registration with a statutory admission system. Any organisation that makes workers available to a third party in the Netherlands must hold an admission before it may legally do so, and hirers will be prohibited from engaging providers that do not hold one.

For a global contingent workforce programme with Dutch demand, this is not a routine compliance update. It is an event that will remove part of your Dutch supplier base, and it carries direct financial exposure for the hiring entity, not only for the supplier.

The timeline that matters

11 November 2025 Wtta adopted.
30 June 2026 Final version of the standards framework, including the equal-pay (gelijkwaardige beloning) component, published.
1 November – 31 December 2026 Notification window at the new Netherlands Labour Market Authority (Nederlandse Autoriteit Uitleenmarkt, NAU). Providers that notify in this window fall under the transitional arrangement.
1 January 2027 Wtta enters into force. Admission becomes the legal requirement to supply labour.
30 June 2027 Reference date for the SNA transitional route: providers holding an SNA certificate on this date may apply for admission without first submitting a Wtta inspection report.
1 January 2028 Enforcement begins. Hirers engaging a non-admitted provider face administrative penalties, reported at up to €90,000 per violation.

What changes for the supplier

Admission is granted by the NAU and depends on meeting a standards framework built substantially on the existing SNA / NEN 4400-1 requirements — reliable payroll administration, correct remittance of payroll tax and social security contributions, identity verification, and correct handling of onward supply. Additional Wtta-specific elements apply, including a financial deposit requirement and the equal-pay standard. Admitted providers appear in a public register.

Two transitional routes exist:

  • The SNA route. A provider holding a valid SNA certificate on 30 June 2027 may apply for admission using that certificate in place of an initial Wtta inspection report. In practice, SNA-certified suppliers are the ones most likely to reach admission without disruption.
  • The notification route. A provider without SNA that notifies the NAU during the 1 November – 31 December 2026 window may complete its application with an inspection report later.

Providers that do neither are exposed to a capacity bottleneck: thousands of Dutch providers require inspection in the same period, and inspection capacity is widely expected to fall short.

What changes for the MSP and the hirer

This is the part most global programmes have not yet operationalised. The Wtta creates a duty on the hiring party to verify that the provider it engages is admitted. The obligation cannot be contracted away to the MSP or to a payroll intermediary, and the penalty attaches to the party doing the hiring.

Three practical consequences:

  1. Your Dutch supplier list will shrink. Some incumbent suppliers — particularly small niche agencies and single-desk specialists — will not obtain admission in time, or at all. Categories currently covered by one or two small suppliers are the ones at risk.
  2. Verification becomes a recurring control, not a one-off onboarding check. Admission can be withdrawn. A supplier that was admitted at onboarding may not be admitted six months later, and the register is the source of truth.
  3. Onward supply is in scope. Where a supplier subcontracts to another provider — common in Dutch staffing — the chain must be admitted too. Programmes that permit sub-supply without visibility are carrying unquantified exposure.

Why Life Sciences programmes are more exposed than most

Three characteristics of the Dutch Life Sciences contingent population amplify the risk.

Supplier concentration. Regulated Life Sciences roles — Qualified Person, GMP quality assurance, CSV and validation, MSAT, bioprocessing, pharmacovigilance — are typically served by a small number of specialist suppliers rather than by the generalist tier. If a specialist supplier fails admission, there is rarely a like-for-like replacement already onboarded.

Heavy reliance on self-employed professionals. A large share of senior Dutch interim capacity in this sector operates on a ZZP basis. That population is already under pressure from renewed enforcement of the Wet DBA on false self-employment. Programmes that responded to Wet DBA by routing ZZP professionals through intermediaries now need those intermediaries to be admitted under the Wtta as well.

Continuity risk carries regulatory weight. In a GMP environment, losing a validation lead or a QP mid-programme is not merely a staffing inconvenience. It can affect batch release, audit readiness and inspection outcomes. Supplier discontinuity converts into compliance risk for the end client.

A supplier-base action plan for programme owners

  1. Inventory your Dutch supply. Identify every provider supplying labour into a Dutch entity, including those reaching you through a master vendor or payroll intermediary.
  2. Ask two questions of each one now. Do you hold a valid SNA / NEN 4400-1 certificate, and will you hold it on 30 June 2027? Have you notified, or will you notify, the NAU in the November–December 2026 window? An evasive answer to either is your risk signal.
  3. Rank your categories by single-supplier dependency. Any Dutch job family covered by one supplier that cannot answer both questions confidently is a continuity gap that needs a second source before 2027, not during 2028.
  4. Update contract and onboarding templates. Add a Wtta admission warranty, an obligation to notify loss or suspension of admission without delay, an explicit position on onward supply, and a right to terminate on loss of admission.
  5. Build register verification into programme governance. Periodic re-checks against the public register, owned by the programme, with an evidenced audit trail.
  6. Onboard contingency suppliers early. Supplier qualification takes months. Onboarding a compliant specialist in 2026 costs far less than sourcing one in a compressed market in 2028.

Where this leaves SIRE Life Sciences

SIRE Life Sciences B.V. (KvK 55616011) is certified to NEN 4400-1 and registered with Stichting Normering Arbeid, which is the certification that underpins the SNA transitional route to Wtta admission. We act as the formal employer for seconded professionals under WAADI, and we supply exclusively into the Life Sciences category — pharmaceuticals, biotechnology, medical devices, clinical research, CMO/CDMO and food sciences — across the Netherlands.

For programmes identifying Dutch Life Sciences coverage gaps ahead of 2027, we are set up to move through supplier qualification and be onboarded into your VMS in advance of the transition rather than during it.

Authoritative sources

This briefing is general information for workforce and procurement professionals and is not legal advice. Requirements and dates under the Wtta continue to be developed in secondary regulation; verify current status against the official sources above before making programme decisions.

Reviewing your Dutch supplier coverage before 2027?

If you are mapping Wtta exposure across a Dutch Life Sciences supplier base, or need a compliant specialist supplier onboarded into an MSP or VMS programme ahead of the transition, we are happy to be a sounding board — including on categories we do not supply.

See our MSP & VMS supplier profile for the Netherlands →
Contact the SIRE supplier & programme team →

Netherlands Life Sciences Contingent Workforce Guide for MSP and procurement teams →

Nederlandse versie: Wtta 2027 voor inleners en MSP-programma’s →

Geschreven door: — SIRE Life Sciences

Chief Executive Officer van SIRE® Life Sciences B.V. (KvK 55616011), gevestigd op het Leiden Bio Science Park in Leiden. Verantwoordelijk voor consultancy, projectmanagement en detachering voor farma, biotech, medtech en clinical research in Nederland.